The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Effect of preventive ( blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial
Open accessAbstract
OBJECTIVE: To determine if the addition of preventive drug treatment (β blocker), brief behavioural migraine management, or their combination improves the outcome of optimised acute treatment in the management of frequent migraine. DESIGN: Randomised placebo controlled trial over 16 months from July 2001 to November 2005. SETTING: Two outpatient sites in Ohio, USA. PARTICIPANTS: 232 adults (mean age 38 years; 79% female) with diagnosis of migraine with or without aura according to International Headache Society classification of headache disorders criteria, who recorded at least three migraines with disability per 30 days (mean 5.5 migraines/30 days), during an optimised run-in of acute treatment. INTERVENTIONS: Addition of one of four preventive treatments to optimised acute treatment: β blocker (n=53), matched placebo (n=55), behavioural migraine management plus placebo (n=55), or behavioural migraine management plus β blocker (n=69). MAIN OUTCOME MEASURE: The primary outcome was change in migraines/30 days; secondary outcomes included change in migraine days/30 days and change in migraine specific quality of life scores. RESULTS: Mixed model analysis showed statistically significant (P≤0.05) differences in outcomes among the four added treatments for both the primary outcome (migraines/30 days) and the two secondary outcomes (change in migraine days/30 days and change in migraine specific quality of life scores). The addition of combined β blocker and behavioural migraine management (-3.3 migraines/30 days, 95% confidence interval -3.2 to -3.5), but not the addition of β blocker alone (-2.1 migraines/30 days, -1.9 to -2.2) or behavioural migraine management alone (-2.2 migraines migraines/30 days, -2.0 to -2.4), improved outcomes compared with optimised acute treatment alone (-2.1 migraines/30 days, -1.9 to -2.2). For a clinically significant (≥50% reduction) in migraines/30 days, the number needed to treat for optimised acute treatment plus combined β blocker and behavioural migraine management was 3.1 compared with optimised acute treatment alone, 2.6 compared with optimised acute treatment plus β blocker, and 3.1 compared with optimised acute treatment plus behavioural migraine management. Results were consistent for the two secondary outcomes, and at both month 10 (the primary endpoint) and month 16. CONCLUSION: The addition of combined β blocker plus behavioural migraine management, but not the addition of β blocker alone or behavioural migraine management alone, improved outcomes of optimised acute treatment. Combined β blocker treatment and behavioural migraine management may improve outcomes in the treatment of frequent migraine. TRIAL REGISTRATION: Clinical trials NCT00910689.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Migraine prevalence, disease burden, and the need for preventive therapy
Lipton, R. B., Bigal, M. E., Diamond, M., Freitag, F., Reed, M. L., & Stewart, W. F. (2007) · Neurology · doi:10.1212/01.wnl.0000252808.97649.21 · Cited by 2,337
Prevalence and Burden of Migraine in the United States: Data From the American Migraine Study II
Lipton, R. B., Stewart, W. F., Diamond, S., Diamond, M. L., & Reed, M. (2001) · Headache: The Journal of Head and Face Pain · doi:10.1046/j.1526-4610.2001.041007646.x · Cited by 2,268
New Appendix Criteria Open for a Broader Concept of Chronic Migraine
Olesen, J., Bousser, M.-G., Diener, H.-C., Dodick, D., First, M., Goadsby, P., Göbel, H., Lainez, M., Lance, J., Lipton, R., et al. (2006) · Cephalalgia · doi:10.1111/j.1468-2982.2006.01172.x · Cited by 909 · cited 1×
“Frequent migraine is also a risk factor for progression from episodic migraine to chronic migraine (at least 15 headache days a month”
BackgroundACCOUNTING FOR DROPOUT BIAS USING MIXED-EFFECTS MODELS
Mallinckrodt, C. H., Clark, W. S., & David, S. R. (2001) · Journal of Biopharmaceutical Statistics · doi:10.1081/bip-100104194 · Cited by 398 · cited 1×
“tests to compare attrition and side effects across the relevant treatment groups. Efficacy analyses were intention to treat analyses that included all randomised participants (n=232). We used a mixed model with fixed effects for treatment (four treatment conditions), time (defined as the natural log of months), and th…”
MethodValidity and Reliability of the Migraine‐Specific Quality of Life Questionnaire (MSQ Version 2.1)
Martin, B. C., Pathak, D. S., Sharfman, M. I., Adelman, J. U., Taylor, F., Kwong, W. J., & Jhingran, P. (2000) · Headache: The Journal of Head and Face Pain · doi:10.1046/j.1526-4610.2000.00030.x · Cited by 299
Handling drop‐out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches
Lane, P. (2008) · Pharmaceutical Statistics · doi:10.1002/pst.267 · Cited by 262
Cited by
Reporting of Patient-Reported Outcomes in Randomized Trials: The CONSORT PRO Extension
Calvert, M., Blazeby, J., Altman, D. G., Revicki, D. A., Moher, D., Brundage, M. D., & CONSORT PRO Group, F. T. (2013) · JAMA · doi:10.1001/jama.2013.879 · Cited by 1,386
Ailani, J., Burch, R. C., Robbins, M. S., & the Board of Directors of the American Headache Society (2021) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.14153 · Cited by 766
American Headache Society (2019) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.13456 · Cited by 567
Migraine prevention with a supraorbital transcutaneous stimulator: A randomized controlled trial
Schoenen, J., Vandersmissen, B., Jeangette, S., Herroelen, L., Vandenheede, M., Gérard, P., & Magis, D. (2013) · Neurology · doi:10.1212/wnl.0b013e3182825055 · Cited by 360
Differential Effectiveness of Placebo Treatments: A Systematic Review of Migraine Prophylaxis
Meissner, K., Fässler, M., Rücker, G., Kleijnen, J., Hróbjartsson, A., Schneider, A., Antes, G., & Linde, K. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.10391 · Cited by 301
Metadata
- Authors
- Holroyd, K. A., Cottrell, C. K., O'Donnell, F. J., Cordingley, G. E., Drew, J. B., Carlson, B. W., & Himawan, L.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2010-09-29
- Volume
- 341
- Issue
- sep29 2
- Pages
- c4871-c4871
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2044736568
- Cited by
- 222
- References
- 6
- FWCI
- 9.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of preventive ( blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial. https://app.cochat.ai/papers/10.1136/bmj.c4871
- The paper
- Holroyd, K. A., Cottrell, C. K., O'Donnell, F. J., Cordingley, G. E., Drew, J. B., Carlson, B. W., & Himawan, L. (2010). Effect of preventive ( blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial. BMJ. https://doi.org/10.1136/bmj.c4871
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.